Emmes calls in telehealth capabilities to expand eClinical platform
28 Sep 2023
AcquisitionClinical Study
Preview
Source: FierceBiotech
Emmes has been busy in recent years, chalking up five acquisitions between 2021 and 2022.
Maryland-based CRO Emmes has added telehealth capabilities to its Advantage eClinical platform, allowing for virtual video calls for trial participants and sites.
The video option, which patients can use by signing into their existing portal, is part of Emmes’ plans to create a digital trial infrastructure that can accommodates all forms of clinical trials from on-site, decentralized, hybrid and fully virtual, the company said in a Sept. 27 press release.
The platform also has the capabilities for data capturing, cleaning and monitoring as well as managing workflow, sample tracking and clinical assessment and engagement tools.
“It's a platform to accelerate the delivery of all types of trial designs through one unified, modular system,” Ching Tian, Emmes’ chief innovation officer, said in the release. “By eliminating the need for sponsors to procure and set up additional point decentralized trial systems, we hope more studies will offer patient-centric options for patients to participate.”
Emmes has been busy in recent years, chalking up five acquisitions between 2021 and 2022. A year ago, it bought Clinical Edge, which offered training and certification of visual function examiners at investigator sites conducting ophthalmic clinical trials.
That followed the acquisition of Plymouth, Massachusetts-based rare disease trials contractor Casimir, U.K.-based rare disease specialist Orphan Reach, German late-phase study-focused contractor Institut Dr. Schauerte and Czech Republic-headquartered Neox.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.